Table 1 Notable ongoing clinical trials in hematological malignancies

Lymphoid neoplasm

NCT02181738

2

Nivolumab

Clinical activity of anti-PD-1 antibody in R/R CHL patients

CheckMate 205

NCT01953692

2

Pembrolizumab

Clinical activity of anti-PD-1 antibody in R/R CHL patients

KEYNOTE-013

NCT02857426

2

Nivolumab

Anti-PD-1 antibody in R/R PCNSL and PTL

NCT02576990

2

Pembrolizumab

Anti-PD-1 antibody in R/R PMBL

KEYNOTE-170

NCT02220842

1

Atezolizumab

Anti-PD-L1 antibody in combination with anti-CD20 antibody to R/R DLBCL or FL

Plasma cell neoplasm

NCT02036502

1

Pembrolizumab

Clinical activity of anti-PD-1, lenalidomide and low-dose dexamethasone in R/R PCM patients shown

KEYNOTE-023

NCT02903381

2

Nivolumab

Lenalidomide, low-dose dexamethasone and anti-PD-1 antibody in smoldering PCM patients

NCT01592370

1

Nivolumab

Clinical activity of anti-PD-1 antibody in R/R PCM patients

NCT02726581

3

Nivolumab

Pomalidomide and dexamethasone with or without anti-PD-1 antibody in R/R PCM patients

CheckMate 602

NCT02579863

3

Pembrolizumab

Pomalidomide and dexamethasone with or without anti-PD-1 antibody in treatment-naïve PCM patients

KEYNOTE-185

Myeloid neoplasms

NCT02530463

2

Nivolumab

HMA, ipilimumab, and anti-PD-1 antibody in MDS patients

NCT01953692

1

Pembrolizumab

Anti-PD-1 antibody in HMA-failed MDS patients

NCT02845297

2

Pembrolizumab

Anti-PD-1 with HMA in R/R AML patients

NCT02275533

2

Nivolumab

Anti-PD-1 antibody as post-remission therapy in AML patients

NCT02117219

1

Durvalumab

Anti-PD-L1 antibody, HMA, and tremelimumab in MDS patients